Toronto, Ontario--(Newsfile Corp. - March 23, 2021) - Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the "Company" or "Datametrex") is pleased to announce that Heath Canada ("HC") has approved the PCL Inc.'s ("PCL") COVID19 AG Rapid test kit ("PCL Antigen"), an antigen point-of-care rapid test device under the Interim Order ("IO") Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19. Datametrex made an application for the PCL Antigen under IO on August 24, 2020, Respecting the Importation and Sale of Medical Devices for use in relation to COVID-19 pursuant to subsection 30.1(1) of the Food and Drugs Act. (link: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/medical-devices/authorized/list.html)
According to the manufacturer, PCL Antigen has a test sensitivity of 94.29% and the test kits are suitable for point of care tests. No extra equipment is needed. They are simple to use, and results are available in 10 minutes. Early detection using rapid tests will also provide further protection to Canada's front-line workers, especially health care professionals.
View the PCL Antigen test manual video by clicking the link: PCL COVID-19 ANTIBODY TEST
The following certifications have been awarded to these PCL Antigen test kits: CE Certificate, Korea KPMG, FIND Listed, UNGM Supplier. Countries includes the EU, 2 countries in the Middle East, Qatar and UAE, India, Russia, 3 countries in Latin America, Guatemala, Ecuador, and Colombia.
"Datametrex has been given another incredible opportunity to sell an additional medical testing device in Canada with the antigen test, with a supplier with outstanding medical devices in PCL. With the highly contagious new variant, and the second wave and possible third wave of COVID-19 in Canada and throughout the world, Datametrex believes an increase in testing capacity is critical to test and protect people," said Marshall Gunter, CEO of Datametrex AI Limited.
The Company's ability to fulfill any purchase order for the PCL Rapid test kits is subject to the availability of inventory at the time of order. Due to the extraordinarily high demand for COVID-19 test, there is volatility in the supply chain and available supply may fluctuate on a daily basis. Datametrex anticipates that it will have little, or no upfront costs associated with importing and selling these test kits.
Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex's mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain.
For additional information on Datametrex and other corporate information, please visit the Company's website at www.datametrex.com.
For further information, please contact:
Marshall Gunter - CEO Phone: (514) 295-2300 Email: firstname.lastname@example.org
Neither the TSX Venture Exchange nor it's Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
All statements included in this press release that address activities, events, or developments that the Company expects, believes, or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections, and other forward-looking statements will prove inaccurate, certain of which are beyond the Company's control. In particular, there is no guarantee that the parties will successfully negotiate and enter into a definitive agreement on mutually acceptable terms or complete the Transaction in the manner contemplated herein, if at all, that the due diligence of any of the parties will be satisfactory, or that the parties will obtain any required board, shareholder, third-party and/or regulatory or other governmental approvals, if any. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not undertake to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.